X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development

By Gabby Migliara  |    October 18, 2021
A new study from economists at the University of Chicago examined the impact that government price-setting policies for medicines, like those in H.R. 3, could have if implemented. The economists...   Read More

Five reasons tying VA prices to Medicare Part D misses the mark

By Nicole Longo  |    September 22, 2021
Some members of Congress are considering a government “negotiation” plan that would tie medicine prices in Medicare to those in the U.S. Department of Veterans Affairs (VA). This misguided approach...   Read More

H.R. 3 threatens access to medicines, future innovation and American jobs

By Gabby Migliara  |    May 4, 2021
In the last election, voters made clear that they want quality, affordable health coverage that works when they need it and lower out-of-pocket costs for medicines. And we can achieve those goals,...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates